Each tablet contains Mifepristone 200 mg.
Mifepristone is prescribed for:
MTPill is prescribed for the medical termination of intrauterine pregnancy through 49 days pregnancy.
For purposes of this treatment, pregnancy is dated from the first day of the last menstrual period in a presumed 28 day cycle with ovulation occurring at mid-cycle.
Any intrauterine device [IUD] should be removed before treatment with MTPill begins.
Patients taking MTPill must take 400 mg of Misoprost two days after taking mifepristone unless a complete abortion has already been confirmed before that time.
Pregnancy termination by surgery is recommended in cases when MTPill and Misoprost fail to cause termination of intrauterine pregnancy.
Treatment with MTPill and Misoprost for the termination of pregnancy requires three office visits by the patient.
MTPill may be administered only in a clinic, medical office, or hospital, by or under the supervision of a gynecologist, able to assess the gestational age of an embryo and to diagnose ectopic pregnancies.
Gynecologist must also be able to provide surgical intervention in cases of incomplete abortion or severe bleeding, or have made plans to provide such care through others, and be able to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.
Day One: MTPill Administration
Three 200 mg tablets (600 mg) of MTPill are taken in a single oral dose.
Day Three: Misoprost Administration
The patient returns to the doctor two days after ingesting MTPill.
Unless abortion has occurred and has been confirmed by clinical examination or ultrasonographic scan, the patient takes two 200 mg tablets (400 mg) of Misoprost orally.
During the period immediately following the administration of Misoprostol, the patient may need medication for cramps or gastrointestinal symptoms.
The patient should be given instructions on what to do if significant discomfort, excessive bleeding or other adverse reactions occur and should be given a phone number to call if she has questions following the administration of the Misoprost.
Day 14: Post-Treatment Examination
Patients will return for a follow-up visit approximately 14 days after the administration of MTPill.
This visit is very important to confirm by clinical examination or ultrasonographic scan that a complete termination of pregnancy has occurred.
Patients who have an ongoing pregnancy at this visit have a risk of fetal malformation resulting from the treatment.
Surgical termination is recommended to manage medical abortion treatment failures.
Administration of MTPill and Misoprost for the termination of pregnancy is contraindicated in patients with any one of the following conditions:
- Chronic adrenal failure;
- Concurrent long-term corticosteroid therapy;
- Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (the treatment procedure will not be effective to terminate an ectopic pregnancy);
- Hemorrhagic disorders or concurrent anticoagulant therapy;
- History of allergy to mifepristone, misoprostol or other prostaglandin;
- Inherited porphyria;
- Iud in place;
Because it is important to have access to appropriate medical care if an emergency develops, the treatment procedure is contraindicated if a patient does not have adequate access to medical facilities equipped to provide emergency treatment of incomplete abortion, blood transfusions, and emergency resuscitation during the period from the first visit until discharged by the administering physician.
- Pack of 3 tablets;